sintilimab: Clinical Trials

65 trials of sintilimab, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

19 recruiting, 15 not yet recruiting, 14 unknown, 10 completed. 65 Phase 3, 16 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 365Recruiting 19, Not yet recruiting 15, Unknown 14, Completed 10, Active not recruiting 5, Terminated 2
Phase 216Unknown 6, Not yet recruiting 5, Recruiting 3, Completed 2

Follow sintilimab: new trials by email Literature Review of sintilimab trials Research Report on sintilimab

Trials (filtered) newest first · largest first

All 65 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Anti-PCSK9 Antibody Tafolecimab and Anti-PD-1 Antibody Sintilimab Combined With Neoadjuvant Chemoradiotherapy for pMMR/ MSS Locally Advanced Rectal Cancer : A Prospective, Multicenter, Randomized, Open-Label, Parallel-Controlled Trial
Short-course radiotherapy, CAPOX (oxaliplatin/capecitabine), Sintilimab - Local Advanced Rectal Cancer, PD-1 Inhibitor
Phase 3Not yet recruitingGuangdong Provincial People's Hospital1482027-01-012026-07-07
Sintilimab Combined With LCCRT Followed by Capeox Chemotherapy in pMMR/MSS/MSI-L Locally Advanced Rectal Cancer
Oxaliplatin, Placebo, radiotherapy - Locally Advanced Rectal Cancer
Phase 3Not yet recruitingInnovent Biologics (Suzhou) Co. Ltd.5002026-11-252026-11-04
SCRT Combined With CAPOX and PD-1 Antibody Versus LCRT Combined With CAPOX for Early Low-lying Rectal Cancer (TORCH-E3)
Short-course radiotherapy, Long-course radiation, PD-1 antibody (Sintilimab) - Early Low Rectal Cancer
Phase 3Not yet recruitingFudan University3942026-11-152026-11-12
ZG005 Plus Bevacizumab vs Sintilimab Plus Bevacizumab as First-Line Therapy for Advanced Hepatocellular
ZG005 for Injection, Bevacizumab ( Avastin), Sintilimab - Hepatocellular Carcinoma
Phase 3RecruitingSuzhou Zelgen Biopharmaceuticals Co.,Ltd6002026-10-202026-11-16
Neoadjuvant Chemoradiotherapy Plus PD-1 Blockade ± CTLA-4 Blockade for High-Risk Locally Advanced Rectal Cancer (pMMR/MSS): A National Multicenter, Prospective, Randomized Controlled Trial
Ipilimumab & Sintilimab, Sintilimab - Locally Advanced Rectal Cancer (LARC)
Phase 2 / Phase 3Not yet recruitingYao Hongwei1202026-10-012026-10-19
Neoadjuvant Chemoradiotherapy Plus PD-1 Blockade ± CTLA-4 Blockade for Low/Intermediate-Risk Locally Advanced Rectal Cancer (pMMR/MSS): A National Multicenter, Prospective, Randomized Controlled Trial
Ipilimumab & Sintilimab, Sintilimab - Locally Advanced Rectal Cancer (LARC)
Phase 2 / Phase 3Not yet recruitingYao Hongwei1202026-10-012026-10-19
Neoadjuvant Sintilimab Plus Chemotherapy for cT2N0M0 Oral Squamous Cell Carcinoma
Sintilimab, Nab-Paclitaxel, Carboplatin - Oral Squamous Cell Carcinoma (OSCC), Head and Neck Squamous Cell Carcinoma
Phase 3Not yet recruitingcaohaotian3002026-10-012026-09-18
QLS31905 in Combination With CAPOX Versus Sintilimab in Combination With CAPOX as First-line Treatment in Patients With GC/GEJ
QLS31905, Sintilimab, Oxaliplatin - Gastric or Gastroesophageal Junction Adenocarcinoma
Phase 3RecruitingQilu Pharmaceutical Co., Ltd.5602026-09-242026-10-19
Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC
Becotatug Vedotin, Sintilimab, Cisplatin - Nasopharyngeal Carcinoma (NPC)
Phase 3RecruitingFirst Affiliated Hospital of Guangxi Medical University2662026-09-082026-11-09
Neoadjuvant and Adjuvant Therapy Studies of Sintilimab Combined With Chemotherapy With or Without Ipilimumab N01 in Resectable Gastric/Gastroesophageal Junction Adenocarcinoma
tegafur, Gimeracil and Oteracil Potassium Capsules, Sintilimab Placebo, Sintilimab - Resectable Gastric/Gastroesophageal Junction Adenocarcinoma
Phase 2 / Phase 3RecruitingInnovent Biopharmaceutical Technology (Hangzhou) Co., LTD.7202026-07-312026-08-14
Retlirafusp Alfa Injection Plus Chemotherapy Versus Investigator's Choice of Anti-PD-1 Antibody Plus Chemotherapy as First-line Treatment for Advanced Gastric Cancer With Liver Metastases
Retlirafusp alfa Injection, Capecitabine, Oxaliplatin - Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma
Phase 3Not yet recruitingPeking University3322026-06-262026-06-30
Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer
Sintilimab, Lenvatinib, Comprehensive Local Consolidative Therapy - Hepatocellular Carcinoma (HCC), Metastases
Phase 3Not yet recruitingTongji Hospital4002026-05-302026-04-17
A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment.
Bevacizumab, Capecitabine, Oxaliplatin - Hepatocellular Carcinoma (HCC)
Phase 2 / Phase 3RecruitingInnovent Biopharmaceutical Technology (Hangzhou) Co., LTD.6802026-03-272026-04-16
Sintilimab Versus Mitomycin in Combination With Capecitabine and IMRT for Limited-stage Anal Squamous Cell Carcinoma
Intensity-Modulated Radiotherapy (IMRT), Capecitabine, Sintilimab - Anal Squamous Cell Carcinoma, Limited-stage
Phase 3RecruitingCancer Institute and Hospital, Chinese Academy of Medical Sciences3502026-03-172026-07-09
Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification
PD1 antibody, Medroxyprogesterone Acetate 500 MG, Megestrol Acetate 160 MG - Endometrial Cancer, Fertility
Phase 2 / Phase 3RecruitingFudan University2602026-01-252026-03-13
Sintilimab Plus Chemotherapy as Neoadjuvant and Adjuvant Treatment for Locally Advanced Oral Squamous Cell Carcinoma
Sintilimab plus nab-paclitaxel and platinum-based chemotherapy, Radical surgery combined with radiotherapy or chemoradiotherapy - Locally Advanced Oral Squamous Cell Carcinoma, Oral Squamous Cell Carcinoma (OSCC)
Phase 3RecruitingQunxing Li,MD1042026-01-012026-01-28
Adjuvant Radiotherapy of Sintilimab Versus TACE for HCC
Sintilimab, radiotherapy, TACE - Hepatocellular Carcinoma (HCC), Radiotherapy, Adjuvant
Phase 3RecruitingCancer Institute and Hospital, Chinese Academy of Medical Sciences2862025-07-102025-09-22
Efficacy and Safety of Fruquintinib Combined With Sintilimab and Stereotactic Body Radiation Therapy (SBRT) for the Second-line and Higher-line Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma With Oligometastatic Progression
Fruquintinib Combined with Sintilimab and Stereotactic Body Radiation Therapy - Gastric Neoplasm
Phase 2 / Phase 3Not yet recruitingQueling Liu302025-06-012025-05-16
PD-1 Antibody Sintilimab Combined With Capecitabine as Adjuvant Therapy for High-Risk Nasopharyngeal Carcinoma
Sintilimab, Capecitabine - Nasopharyngeal Carcinoma (NPC)
Phase 3Not yet recruitingSun Yat-sen University6642025-05-012025-04-02
Neoadjuvant Apatinib Combined With Sintilimab and Perioperative SOX Versus Neoadjuvant Sintilimab Combined With Perioperative SOX for Intestinal Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
Neoadjuvant apatinib combined with sintilimab and perioperative SOX, Neoadjuvant sintilimab combined with perioperative SOX - Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]), Neoadjuvant Therapy
Phase 3RecruitingZuoyi Jiao6822025-04-152025-04-22

Showing 20 of 65. Sign in to see all of them.

Conditions studied

Carcinoma, Hepatocellular (12)  ·  Stomach Neoplasms (5)  ·  Carcinoma, Non-Small-Cell Lung (4)  ·  Colorectal Neoplasms (4)  ·  Esophageal Neoplasms (4)  ·  Esophageal Squamous Cell Carcinoma (4)  ·  Endometrial Neoplasms (2)  ·  Nasopharyngeal Carcinoma (2)  ·  Squamous Cell Carcinoma of Head and Neck (2)  ·  Anus Neoplasms (1)  ·  Carcinoma, Squamous Cell (1)  ·  Esophageal Diseases (1)  ·  Gastrointestinal Diseases (1)  ·  Hepatoblastoma (1)  ·  Liver Neoplasms (1)

Sponsors

Innovent Biologics (Suzhou) Co. Ltd. (14)  ·  Sun Yat-sen University (6)  ·  Tongji Hospital (3)  ·  Cancer Institute and Hospital, Chinese Academy of Medical Sciences (2)  ·  Fudan University (2)  ·  Hutchmed (2)  ·  Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. (2)  ·  Qilu Pharmaceutical Co., Ltd. (2)  ·  Second Affiliated Hospital, Zhejiang University, School of Medicine (2)  ·  Yao Hongwei (2)  ·  Beijing Friendship Hospital (1)  ·  Changzhou Cancer Hospital of Soochow University (1)  ·  Chinese Academy of Medical Sciences (1)  ·  Chipscreen Biosciences, Ltd. (1)  ·  First Affiliated Hospital Xi'an Jiaotong University (1)

Countries

China (59)  ·  Australia (1)  ·  Belgium (1)  ·  France (1)  ·  Hungary (1)  ·  Spain (1)  ·  United States (1)

Top investigators

Caicun Zhou (1)  ·  Chen Li, PhD (1)  ·  Degan Lu, professor (1)  ·  Dingwei Ye (1)  ·  Hao Feng (1)  ·  Jason Wu (1)  ·  Jia Fan (1)  ·  Jin Yang, Doctor (1)  ·  Jing Jin, MD, PhD (1)  ·  Jinjun Ye (1)  ·  Jinsong Li, MD, PhD (1)  ·  Jun Huang, PhD. (1)  ·  Jun Ma, MD (1)  ·  Kangshun Zhu, MD (1)

Results publications

PMID 32781263, PMID 29229461, PMID 29543938, PMID 30119083, PMID 30285222, PMID 30558224, PMID 30612710, PMID 30955977, PMID 31378236, PMID 31402780, PMID 31560378, PMID 32997907, PMID 34048947, PMID 34143971, PMID 34358724, PMID 35440464, PMID 35908558, PMID 35917647, PMID 36336841, PMID 37139963, PMID 37156249, PMID 37464378, PMID 37737025, PMID 38051328, PMID 38353107, PMID 38594905, PMID 38800802, PMID 38824941, PMID 39020518, PMID 39084935, PMID 39267574, PMID 39395411, PMID 39438442, PMID 39884222, PMID 40467307, PMID 40532178, PMID 40651471, PMID 40845854, PMID 40851062, PMID 41629425, PMID 41791006, PMID 42820658